ID   P4K2A_HUMAN             Reviewed;         479 AA.
AC   Q9BTU6; D3DR59; Q9NSG8;
DT   01-MAY-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   12-APR-2017, entry version 133.
DE   RecName: Full=Phosphatidylinositol 4-kinase type 2-alpha;
DE            EC=2.7.1.67 {ECO:0000269|PubMed:11279162, ECO:0000269|PubMed:20388919, ECO:0000269|PubMed:24675427, ECO:0000269|PubMed:25168678};
DE   AltName: Full=Phosphatidylinositol 4-kinase type II-alpha;
GN   Name=PI4K2A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, SUBCELLULAR LOCATION,
RP   IDENTIFICATION BY MASS SPECTROMETRY, CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=11279162; DOI=10.1074/jbc.M100982200;
RA   Minogue S., Anderson J.S., Waugh M.G., dos Santos M., Corless S.,
RA   Cramer R., Hsuan J.J.;
RT   "Cloning of a human type II phosphatidylinositol 4-kinase reveals a
RT   novel lipid kinase family.";
RL   J. Biol. Chem. 276:16635-16640(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 222-479.
RC   TISSUE=Amygdala;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-47 AND SER-51, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [8]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16443754; DOI=10.1242/jcs.02752;
RA   Minogue S., Waugh M.G., De Matteis M.A., Stephens D.J.,
RA   Berditchevski F., Hsuan J.J.;
RT   "Phosphatidylinositol 4-kinase is required for endosomal trafficking
RT   and degradation of the EGF receptor.";
RL   J. Cell Sci. 119:571-581(2006).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-47 AND SER-51, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-47 AND SER-51, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=20388919; DOI=10.1194/jlr.M005751;
RA   Minogue S., Chu K.M., Westover E.J., Covey D.F., Hsuan J.J.,
RA   Waugh M.G.;
RT   "Relationship between phosphatidylinositol 4-phosphate synthesis,
RT   membrane organization, and lateral diffusion of PI4KIIalpha at the
RT   trans-Golgi network.";
RL   J. Lipid Res. 51:2314-2324(2010).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-5; SER-9 AND SER-47, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   INTERACTION WITH BLOC1S5 AND DTNBP1.
RX   PubMed=21998198; DOI=10.1091/mbc.E11-07-0592;
RA   Larimore J., Tornieri K., Ryder P.V., Gokhale A., Zlatic S.A.,
RA   Craige B., Lee J.D., Talbot K., Pare J.F., Smith Y., Faundez V.;
RT   "The schizophrenia susceptibility factor dysbindin and its associated
RT   complex sort cargoes from cell bodies to the synapse.";
RL   Mol. Biol. Cell 22:4854-4867(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-47 AND SER-51, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [16]
RP   SUBCELLULAR LOCATION, INTERACTION WITH ITCH, UBIQUITINATION, AND
RP   FUNCTION.
RX   PubMed=23146885; DOI=10.1038/embor.2012.164;
RA   Mossinger J., Wieffer M., Krause E., Freund C., Gerth F., Krauss M.,
RA   Haucke V.;
RT   "Phosphatidylinositol 4-kinase IIalpha function at endosomes is
RT   regulated by the ubiquitin ligase Itch.";
RL   EMBO Rep. 13:1087-1094(2012).
RN   [17]
RP   SUBCELLULAR LOCATION, PALMITOYLATION AT CYS-174; CYS-175; CYS-177 AND
RP   CYS-178, AND MUTAGENESIS OF 174-CYS--CYS-178.
RX   PubMed=22535966; DOI=10.1074/jbc.M112.348094;
RA   Lu D., Sun H.Q., Wang H., Barylko B., Fukata Y., Fukata M.,
RA   Albanesi J.P., Yin H.L.;
RT   "Phosphatidylinositol 4-kinase IIalpha is palmitoylated by Golgi-
RT   localized palmitoyltransferases in cholesterol-dependent manner.";
RL   J. Biol. Chem. 287:21856-21865(2012).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-5; SER-9; SER-47 AND
RP   SER-51, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-44; SER-47 AND SER-51,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.77 ANGSTROMS) OF 76-172 AND 180-468 IN
RP   COMPLEX WITH ATP, FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF
RP   LYS-152; ASN-163; 165-LYS--LYS-172; ARG-275; ASP-308 AND GLN-445.
RX   PubMed=25168678; DOI=10.15252/embr.201438841;
RA   Baumlova A., Chalupska D., Rozycki B., Jovic M., Wisniewski E.,
RA   Klima M., Dubankova A., Kloer D.P., Nencka R., Balla T., Boura E.;
RT   "The crystal structure of the phosphatidylinositol 4-kinase IIalpha.";
RL   EMBO Rep. 15:1085-1092(2014).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.95 ANGSTROMS) OF 78-453 IN COMPLEX WITH ADP,
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   ARG-129; LYS-152; 157-GLU--TYR-159; LYS-165; TRP-166; LYS-168;
RP   LYS-172; 174-CYS--CYS-178; LEU-184; PHE-263; ASP-269; ARG-275;
RP   ARG-276; ILE-345; LEU-349; TRP-359; TYR-365 AND TRP-368.
RX   PubMed=24675427; DOI=10.1038/ncomms4552;
RA   Zhou Q., Li J., Yu H., Zhai Y., Gao Z., Liu Y., Pang X., Zhang L.,
RA   Schulten K., Sun F., Chen C.;
RT   "Molecular insights into the membrane-associated phosphatidylinositol
RT   4-kinase IIalpha.";
RL   Nat. Commun. 5:3552-3552(2014).
CC   -!- FUNCTION: Membrane-bound phosphatidylinositol-4 kinase (PI4-
CC       kinase) that catalyzes the phosphorylation of phosphatidylinositol
CC       (PI) to phosphatidylinositol 4-phosphate (PI4P), a lipid that
CC       plays important roles in endocytosis, Golgi function, protein
CC       sorting and membrane trafficking and is required for prolonged
CC       survival of neurons. Besides, phosphorylation of
CC       phosphatidylinositol (PI) to phosphatidylinositol 4-phosphate
CC       (PI4P) is the first committed step in the generation of
CC       phosphatidylinositol 4,5-bisphosphate (PIP2), a precursor of the
CC       second messenger inositol 1,4,5-trisphosphate (InsP3).
CC       {ECO:0000269|PubMed:11279162, ECO:0000269|PubMed:16443754,
CC       ECO:0000269|PubMed:20388919, ECO:0000269|PubMed:23146885,
CC       ECO:0000269|PubMed:24675427, ECO:0000269|PubMed:25168678,
CC       ECO:0000305}.
CC   -!- CATALYTIC ACTIVITY: ATP + 1-phosphatidyl-1D-myo-inositol = ADP +
CC       1-phosphatidyl-1D-myo-inositol 4-phosphate.
CC       {ECO:0000269|PubMed:11279162, ECO:0000269|PubMed:20388919,
CC       ECO:0000269|PubMed:24675427, ECO:0000269|PubMed:25168678}.
CC   -!- SUBUNIT: Associates with the BLOC-1 and the AP-3 complexes; the
CC       BLOC-1 complex is required for optimal binding of PI4K2A to the
CC       AP-3 complex. Interacts with BLOC1S5 and DTNBP1 (PubMed:21998198).
CC       Interacts with FOS; this interaction may enhance
CC       phosphatidylinositol phosphorylation activity (By similarity).
CC       Interacts with ITCH (PubMed:23146885).
CC       {ECO:0000250|UniProtKB:Q2TBE6, ECO:0000269|PubMed:21998198,
CC       ECO:0000269|PubMed:23146885}.
CC   -!- INTERACTION:
CC       Q96J02:ITCH; NbExp=5; IntAct=EBI-3239392, EBI-1564678;
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus, trans-Golgi network
CC       membrane {ECO:0000269|PubMed:16443754,
CC       ECO:0000269|PubMed:22535966}; Lipid-anchor
CC       {ECO:0000269|PubMed:22535966}. Membrane raft
CC       {ECO:0000269|PubMed:11279162}. Cell projection, dendrite
CC       {ECO:0000250|UniProtKB:Q2TBE6}. Cell junction, synapse,
CC       presynaptic cell membrane {ECO:0000250|UniProtKB:Q2TBE6}. Cell
CC       junction, synapse, synaptosome {ECO:0000250|UniProtKB:Q2TBE6}.
CC       Mitochondrion {ECO:0000250|UniProtKB:Q2TBE6}. Endosome
CC       {ECO:0000269|PubMed:16443754, ECO:0000269|PubMed:23146885}.
CC       Cytoplasmic vesicle {ECO:0000269|PubMed:16443754}. Membrane
CC       {ECO:0000269|PubMed:24675427}; Lipid-anchor
CC       {ECO:0000269|PubMed:24675427}. Cell membrane
CC       {ECO:0000269|PubMed:11279162, ECO:0000269|PubMed:16443754}.
CC       Note=Localized in neuronal cell body. Transported from neuronal
CC       cell body to neuron projections in a BLOC-1- and AP-3-complexes-
CC       dependent manner. Enriched in neurite tips and neuron projections
CC       in a BLOC-1- and AP-3-complexes-dependent manner (By similarity).
CC       Found in subdomains of the plasma membrane termed non-caveolar
CC       membrane rafts. {ECO:0000250|UniProtKB:Q2TBE6,
CC       ECO:0000250|UniProtKB:Q99M64}.
CC   -!- TISSUE SPECIFICITY: Widely expressed. Highest expression is
CC       observed in kidney, brain, heart, skeletal muscle, and placenta
CC       and lowest expression is observed in colon, thymus, and small
CC       intestine. {ECO:0000269|PubMed:11279162}.
CC   -!- PTM: Palmitoylated by ZDHHC3 and ZDHHC7 in the CCPCC motif.
CC       Palmitoylation is cholesterol-dependent, and required for TGN
CC       localization. {ECO:0000269|PubMed:22535966}.
CC   -!- PTM: Ubiquitinated by ITCH; this does not lead to proteasomal
CC       degradation. {ECO:0000269|PubMed:23146885}.
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. Type II PI4K
CC       subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ303098; CAC38065.1; -; mRNA.
DR   EMBL; BT007330; AAP35994.1; -; mRNA.
DR   EMBL; AL355315; CAI15460.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49906.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49907.1; -; Genomic_DNA.
DR   EMBL; BC003167; AAH03167.1; -; mRNA.
DR   EMBL; AL353952; CAB89254.1; -; mRNA.
DR   CCDS; CCDS7469.1; -.
DR   PIR; T48687; T48687.
DR   RefSeq; NP_060895.1; NM_018425.3.
DR   UniGene; Hs.25300; -.
DR   PDB; 4HND; X-ray; 3.20 A; A/B=78-453.
DR   PDB; 4HNE; X-ray; 2.95 A; A/B=78-453.
DR   PDB; 4PLA; X-ray; 2.77 A; A=180-468.
DR   PDB; 4YC4; X-ray; 2.58 A; A=180-468.
DR   PDB; 5EUT; X-ray; 2.80 A; A=179-468.
DR   PDB; 5I0N; X-ray; 2.28 A; A=180-468.
DR   PDBsum; 4HND; -.
DR   PDBsum; 4HNE; -.
DR   PDBsum; 4PLA; -.
DR   PDBsum; 4YC4; -.
DR   PDBsum; 5EUT; -.
DR   PDBsum; 5I0N; -.
DR   ProteinModelPortal; Q9BTU6; -.
DR   SMR; Q9BTU6; -.
DR   BioGrid; 120639; 22.
DR   IntAct; Q9BTU6; 7.
DR   STRING; 9606.ENSP00000359665; -.
DR   BindingDB; Q9BTU6; -.
DR   ChEMBL; CHEMBL2251; -.
DR   GuidetoPHARMACOLOGY; 2498; -.
DR   iPTMnet; Q9BTU6; -.
DR   PhosphoSitePlus; Q9BTU6; -.
DR   SwissPalm; Q9BTU6; -.
DR   BioMuta; PI4K2A; -.
DR   DMDM; 74752344; -.
DR   EPD; Q9BTU6; -.
DR   MaxQB; Q9BTU6; -.
DR   PaxDb; Q9BTU6; -.
DR   PeptideAtlas; Q9BTU6; -.
DR   PRIDE; Q9BTU6; -.
DR   DNASU; 55361; -.
DR   Ensembl; ENST00000370631; ENSP00000359665; ENSG00000155252.
DR   GeneID; 55361; -.
DR   KEGG; hsa:55361; -.
DR   UCSC; uc001kog.2; human.
DR   CTD; 55361; -.
DR   DisGeNET; 55361; -.
DR   GeneCards; PI4K2A; -.
DR   HGNC; HGNC:30031; PI4K2A.
DR   HPA; CAB030649; -.
DR   HPA; HPA076857; -.
DR   MIM; 609763; gene.
DR   neXtProt; NX_Q9BTU6; -.
DR   OpenTargets; ENSG00000155252; -.
DR   PharmGKB; PA162399304; -.
DR   eggNOG; KOG2381; Eukaryota.
DR   eggNOG; ENOG410XP06; LUCA.
DR   GeneTree; ENSGT00390000010434; -.
DR   HOGENOM; HOG000294076; -.
DR   HOVERGEN; HBG059542; -.
DR   InParanoid; Q9BTU6; -.
DR   KO; K13711; -.
DR   OMA; CLIPLNG; -.
DR   OrthoDB; EOG091G09F3; -.
DR   PhylomeDB; Q9BTU6; -.
DR   TreeFam; TF314740; -.
DR   BioCyc; MetaCyc:HS00573-MONOMER; -.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-HSA-1660514; Synthesis of PIPs at the Golgi membrane.
DR   Reactome; R-HSA-1660516; Synthesis of PIPs at the early endosome membrane.
DR   SIGNOR; Q9BTU6; -.
DR   ChiTaRS; PI4K2A; human.
DR   GeneWiki; PI4K2A; -.
DR   GenomeRNAi; 55361; -.
DR   PRO; PR:Q9BTU6; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000155252; -.
DR   CleanEx; HS_PI4K2A; -.
DR   Genevisible; Q9BTU6; HS.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0031410; C:cytoplasmic vesicle; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; ISS:UniProtKB.
DR   GO; GO:0005768; C:endosome; ISS:UniProtKB.
DR   GO; GO:0035838; C:growing cell tip; ISS:UniProtKB.
DR   GO; GO:0044231; C:host cell presynaptic membrane; ISS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031224; C:intrinsic component of membrane; IDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; ISS:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0042734; C:presynaptic membrane; ISS:UniProtKB.
DR   GO; GO:0005802; C:trans-Golgi network; IBA:GO_Central.
DR   GO; GO:0004430; F:1-phosphatidylinositol 4-kinase activity; IDA:UniProtKB.
DR   GO; GO:0035651; F:AP-3 adaptor complex binding; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; NAS:UniProtKB.
DR   GO; GO:0007032; P:endosome organization; IBA:GO_Central.
DR   GO; GO:0007030; P:Golgi organization; IBA:GO_Central.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0046854; P:phosphatidylinositol phosphorylation; IDA:UniProtKB.
DR   InterPro; IPR000403; PI3/4_kinase_cat_dom.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Cell junction; Cell membrane;
KW   Cell projection; Complete proteome; Cytoplasmic vesicle; Endosome;
KW   Golgi apparatus; Kinase; Lipoprotein; Membrane; Mitochondrion;
KW   Nucleotide-binding; Palmitate; Phosphoprotein; Reference proteome;
KW   Synapse; Synaptosome; Transferase; Ubl conjugation.
FT   CHAIN         1    479       Phosphatidylinositol 4-kinase type 2-
FT                                alpha.
FT                                /FTId=PRO_0000285158.
FT   DOMAIN      133    438       PI3K/PI4K.
FT   NP_BIND     131    137       ATP. {ECO:0000269|PubMed:24675427,
FT                                ECO:0000269|PubMed:25168678}.
FT   NP_BIND     261    264       ATP. {ECO:0000269|PubMed:24675427,
FT                                ECO:0000269|PubMed:25168678}.
FT   REGION      157    159       Important for substrate binding.
FT                                {ECO:0000305|PubMed:24675427}.
FT   REGION      165    178       Important for interaction with membranes.
FT                                {ECO:0000305|PubMed:24675427,
FT                                ECO:0000305|PubMed:25168678}.
FT   REGION      268    276       Important for interaction with membranes.
FT                                {ECO:0000305|PubMed:24675427}.
FT   REGION      359    368       Important for interaction with membranes.
FT                                {ECO:0000305|PubMed:24675427}.
FT   COMPBIAS     39     42       Poly-Ala.
FT   COMPBIAS     65     97       Ala-rich.
FT   BINDING     152    152       ATP. {ECO:0000269|PubMed:24675427,
FT                                ECO:0000269|PubMed:25168678}.
FT   BINDING     346    346       ATP. {ECO:0000269|PubMed:24675427,
FT                                ECO:0000269|PubMed:25168678}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:22814378,
FT                                ECO:0000244|PubMed:25944712}.
FT   MOD_RES       5      5       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES       9      9       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      44     44       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      47     47       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES      51     51       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     462    462       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q99M64}.
FT   LIPID       174    174       S-palmitoyl cysteine.
FT                                {ECO:0000305|PubMed:22535966,
FT                                ECO:0000305|PubMed:24675427}.
FT   LIPID       175    175       S-palmitoyl cysteine.
FT                                {ECO:0000305|PubMed:22535966,
FT                                ECO:0000305|PubMed:24675427}.
FT   LIPID       177    177       S-palmitoyl cysteine.
FT                                {ECO:0000305|PubMed:22535966,
FT                                ECO:0000305|PubMed:24675427}.
FT   LIPID       178    178       S-palmitoyl cysteine.
FT                                {ECO:0000305|PubMed:22535966,
FT                                ECO:0000305|PubMed:24675427}.
FT   MUTAGEN     129    129       R->E: Reduces enzyme activity, probably
FT                                due to impaired membrane-association;
FT                                when associated with E-275 and E-276.
FT                                {ECO:0000269|PubMed:24675427}.
FT   MUTAGEN     152    152       K->A: Abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:24675427,
FT                                ECO:0000269|PubMed:25168678}.
FT   MUTAGEN     157    159       EPY->APA: Abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:24675427}.
FT   MUTAGEN     163    163       N->A: Reduces enzyme activity.
FT                                {ECO:0000269|PubMed:25168678}.
FT   MUTAGEN     165    172       KWTKWLQK->AAAAAAAA: Abolishes enzyme
FT                                activity. {ECO:0000269|PubMed:25168678}.
FT   MUTAGEN     165    165       K->A: Abolishes enzyme activity; when
FT                                associated with A-168 and A-172.
FT                                {ECO:0000269|PubMed:24675427}.
FT   MUTAGEN     166    166       W->A: Reduces enzyme activity.
FT                                {ECO:0000269|PubMed:24675427}.
FT   MUTAGEN     168    168       K->A: Abolishes enzyme activity; when
FT                                associated with A-165 and A-172.
FT                                {ECO:0000269|PubMed:24675427}.
FT   MUTAGEN     172    172       K->A: Abolishes enzyme activity; when
FT                                associated with A-165 and A-168.
FT                                {ECO:0000269|PubMed:24675427}.
FT   MUTAGEN     174    178       CCPCC->FFPFF: No effect on membrane-
FT                                association.
FT                                {ECO:0000269|PubMed:24675427}.
FT   MUTAGEN     174    178       CCPCC->SSPSS: Abolishes palmitoylation
FT                                and impairs membrane-association.
FT                                {ECO:0000269|PubMed:22535966,
FT                                ECO:0000269|PubMed:24675427}.
FT   MUTAGEN     184    184       L->A: Abolishes enzyme activity; when
FT                                associated with A-349.
FT                                {ECO:0000269|PubMed:24675427}.
FT   MUTAGEN     263    263       F->A: Abolishes enzyme activity; when
FT                                associated with A-345.
FT                                {ECO:0000269|PubMed:24675427}.
FT   MUTAGEN     269    269       D->A: Reduces enzyme activity by half.
FT                                {ECO:0000269|PubMed:24675427}.
FT   MUTAGEN     275    275       R->A: Reduces enzyme activity.
FT                                {ECO:0000269|PubMed:25168678}.
FT   MUTAGEN     275    275       R->E: Reduces enzyme activity, probably
FT                                due to impaired membrane-association;
FT                                when associated with E-129 and E-276.
FT                                {ECO:0000269|PubMed:24675427}.
FT   MUTAGEN     276    276       R->E: Reduces enzyme activity, probably
FT                                due to impaired membrane-association;
FT                                when associated with E-129 and E-275.
FT                                {ECO:0000269|PubMed:24675427}.
FT   MUTAGEN     308    308       D->A: Abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:25168678}.
FT   MUTAGEN     345    345       I->A: Abolishes enzyme activity; when
FT                                associated with A-263.
FT                                {ECO:0000269|PubMed:24675427}.
FT   MUTAGEN     349    349       L->A: Abolishes enzyme activity; when
FT                                associated with A-184.
FT                                {ECO:0000269|PubMed:24675427}.
FT   MUTAGEN     359    359       W->A: Strongly reduced enzyme activity,
FT                                probably due to impaired membrane-
FT                                association. Abolishes enzyme activity;
FT                                when associated with A-365 and A-368.
FT                                {ECO:0000269|PubMed:24675427}.
FT   MUTAGEN     365    365       Y->A: Reduces enzyme activity, probably
FT                                due to impaired membrane-association.
FT                                Abolishes enzyme activity; when
FT                                associated with A-368 and A-359.
FT                                {ECO:0000269|PubMed:24675427}.
FT   MUTAGEN     368    368       W->A: Reduces enzyme activity, probably
FT                                due to impaired membrane-association.
FT                                Abolishes enzyme activity; when
FT                                associated with A-359 and A-365.
FT                                {ECO:0000269|PubMed:24675427}.
FT   MUTAGEN     445    445       Q->A: Reduces enzyme activity.
FT                                {ECO:0000269|PubMed:25168678}.
FT   HELIX        78     93       {ECO:0000244|PDB:4HNE}.
FT   HELIX        95     99       {ECO:0000244|PDB:4HNE}.
FT   HELIX       108    122       {ECO:0000244|PDB:4HNE}.
FT   STRAND      131    133       {ECO:0000244|PDB:4HNE}.
FT   STRAND      138    141       {ECO:0000244|PDB:4HNE}.
FT   STRAND      147    153       {ECO:0000244|PDB:4HNE}.
FT   HELIX       154    156       {ECO:0000244|PDB:4HNE}.
FT   HELIX       167    171       {ECO:0000244|PDB:4HNE}.
FT   HELIX       189    203       {ECO:0000244|PDB:5I0N}.
FT   STRAND      211    216       {ECO:0000244|PDB:5I0N}.
FT   HELIX       225    231       {ECO:0000244|PDB:5I0N}.
FT   STRAND      235    237       {ECO:0000244|PDB:4HNE}.
FT   STRAND      249    251       {ECO:0000244|PDB:4HNE}.
FT   STRAND      256    262       {ECO:0000244|PDB:5I0N}.
FT   STRAND      266    269       {ECO:0000244|PDB:4PLA}.
FT   HELIX       270    279       {ECO:0000244|PDB:5I0N}.
FT   HELIX       284    304       {ECO:0000244|PDB:5I0N}.
FT   STRAND      313    318       {ECO:0000244|PDB:5I0N}.
FT   STRAND      339    344       {ECO:0000244|PDB:5I0N}.
FT   TURN        359    361       {ECO:0000244|PDB:5I0N}.
FT   HELIX       365    368       {ECO:0000244|PDB:5I0N}.
FT   HELIX       370    373       {ECO:0000244|PDB:5I0N}.
FT   HELIX       378    388       {ECO:0000244|PDB:5I0N}.
FT   HELIX       391    405       {ECO:0000244|PDB:5I0N}.
FT   HELIX       413    435       {ECO:0000244|PDB:5I0N}.
FT   HELIX       440    444       {ECO:0000244|PDB:5I0N}.
SQ   SEQUENCE   479 AA;  54022 MW;  9C9F4CE23F197BBD CRC64;
     MDETSPLVSP ERAQPPDYTF PSGSGAHFPQ VPGGAVRVAA AAGSGPSPPG SPGHDRERQP
     LLDRARGAAA QGQTQTVAAQ AQALAAQAAA AAHAAQAHRE RNEFPEDPEF EAVVRQAELA
     IERCIFPERI YQGSSGSYFV KDPQGRIIAV FKPKNEEPYG HLNPKWTKWL QKLCCPCCFG
     RDCLVLNQGY LSEAGASLVD QKLELNIVPR TKVVYLASET FNYSAIDRVK SRGKRLALEK
     VPKVGQRFNR IGLPPKVGSF QLFVEGYKDA DYWLRRFEAE PLPENTNRQL LLQFERLVVL
     DYIIRNTDRG NDNWLIKYDC PMDSSSSRDT DWVVVKEPVI KVAAIDNGLA FPLKHPDSWR
     AYPFYWAWLP QAKVPFSQEI KDLILPKISD PNFVKDLEED LYELFKKDPG FDRGQFHKQI
     AVMRGQILNL TQALKDNKSP LHLVQMPPVI VETARSHQRS SSESYTQSFQ SRKPFFSWW
//
